159 related articles for article (PubMed ID: 30734088)
1. Duration of anticoagulant therapy and VTE recurrence in patients with cancer.
Khorana AA; McCrae KR; Milentijevic D; Fortier J; Nelson WW; Laliberté F; Crivera C; Lefebvre P; Schein J
Support Care Cancer; 2019 Oct; 27(10):3833-3840. PubMed ID: 30734088
[TBL] [Abstract][Full Text] [Related]
2. Incremental health care resource utilization and economic burden of venous thromboembolism recurrence from a U.S. payer perspective.
Lin J; Lingohr-Smith M; Kwong WJ
J Manag Care Pharm; 2014 Feb; 20(2):174-86. PubMed ID: 24456319
[TBL] [Abstract][Full Text] [Related]
3. One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events.
Chen SY; Wu N; Gulseth M; LaMori J; Bookhart BK; Boulanger L; Fields L; Schein J
J Manag Care Pharm; 2013 May; 19(4):291-301. PubMed ID: 23627575
[TBL] [Abstract][Full Text] [Related]
4. Association between anticoagulant treatment duration and risk of venous thromboembolism recurrence and bleeding in clinical practice.
Kaatz S; Fu AC; AbuDagga A; LaMori J; Bookhart BK; Damaraju CV; Tan H; Schein J; Nutescu E
Thromb Res; 2014 Oct; 134(4):807-13. PubMed ID: 25127013
[TBL] [Abstract][Full Text] [Related]
5. Weekly risk of venous thromboembolism recurrence in patients receiving oral anticoagulants.
Laliberté F; Coleman CI; Bookhart B; Lefebvre P; Cloutier M; Damaraju CV; Schein JR; Kaatz S
Curr Med Res Opin; 2014 Aug; 30(8):1513-20. PubMed ID: 24738644
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
7. Healthcare resource utilization and costs associated with venous thromboembolism recurrence in patients with cancer.
Khorana AA; McCrae KR; Milentijevic D; Laliberté F; Lejeune D; Crivera C; Lefebvre P
J Med Econ; 2020 Apr; 23(4):323-329. PubMed ID: 31818164
[No Abstract] [Full Text] [Related]
8. Risk of recurrent venous thromboembolism in patients with HIV infection: A nationwide cohort study.
Rokx C; Borjas Howard JF; Smit C; Wit FW; Pieterman ED; Reiss P; Cannegieter SC; Lijfering WM; Meijer K; Bierman W; Tichelaar V; Rijnders BJA;
PLoS Med; 2020 May; 17(5):e1003101. PubMed ID: 32407386
[TBL] [Abstract][Full Text] [Related]
9. Optimal duration of Vitamin K antagonists anticoagulant therapy after venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials.
Wang W; Su Y; Wu C; Sun Y; Dai N; Chen W; Zhang J; Xu Y; Brindis RG; Xu D; Li J
BMC Cardiovasc Disord; 2020 Feb; 20(1):53. PubMed ID: 32013892
[TBL] [Abstract][Full Text] [Related]
10. Predictors of recurrence of cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a multicenter cohort study.
Lapébie FX; Bura-Rivière A; Espitia O; Bongard V; Ciammaichella MM; Martínez JG; Sigüenza P; Giménez JC; Bertoletti L; Monreal M
J Thromb Haemost; 2023 Aug; 21(8):2189-2201. PubMed ID: 37068594
[TBL] [Abstract][Full Text] [Related]
11. Is Adherence to the American College of Chest Physicians Recommended Anticoagulation Treatment Duration Associated With Different Outcomes Among Patients With Venous Thromboembolism?
Spyropoulos AC; Preblick R; Kwong WJ; Lingohr-Smith M; Lin J
Clin Appl Thromb Hemost; 2017 Sep; 23(6):532-541. PubMed ID: 27899520
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of rivaroxaban versus warfarin in patients with provoked venous thromboembolism.
Coleman CI; Turpie AGG; Bunz TJ; Beyer-Westendorf J
J Thromb Thrombolysis; 2018 Oct; 46(3):339-345. PubMed ID: 29881958
[TBL] [Abstract][Full Text] [Related]
13. [Risk factors of venous thromboembolism recurrence and the predictive value of simplified pulmonary embolism severity index in medical inpatients].
Shi CL; Zhou HX; Tang YJ; Wang L; Yi Q; Liang ZA
Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(14):1112-5. PubMed ID: 27095779
[TBL] [Abstract][Full Text] [Related]
14. Utilization of parenteral anticoagulants and warfarin: impact on the risk of venous thromboembolism recurrence in the outpatient setting.
Cai J; Preblick R; Zhang Q; Kwong WJ
Am Health Drug Benefits; 2014 Nov; 7(8):444-51. PubMed ID: 25558306
[TBL] [Abstract][Full Text] [Related]
15. Venous Thromboembolism Recurrence in Latvian Population: Single University Hospital Data.
Ģībietis V; Kigitoviča D; Strautmane S; Meilande K; Kalējs VR; Zaičenko A; Maķe K; Lejnieks A; Skride A
Medicina (Kaunas); 2019 Aug; 55(9):. PubMed ID: 31438542
[No Abstract] [Full Text] [Related]
16. Clinical characteristics and treatment patterns of patients with venous thromboembolism (VTE) transitioning from hospital to post-discharge settings.
Burton T; Hlavacek P; Guo JD; Rosenblatt L; Mardekian J; Ferri M; Russ C; Kline JA
Hosp Pract (1995); 2020 Oct; 48(4):196-205. PubMed ID: 32720816
[TBL] [Abstract][Full Text] [Related]
17. Clinical Outcomes of Incidental Venous Thromboembolism in Cancer and Noncancer Patients: The SWIss Venous ThromboEmbolism Registry (SWIVTER).
Spirk D; Sebastian T; Barco S; Banyai M; Beer JH; Mazzolai L; Baldi T; Aujesky D; Hayoz D; Engelberger RP; Kaeslin T; Korte W; Escher R; Husmann M; Blondon M; Kucher N
Thromb Haemost; 2021 May; 121(5):641-649. PubMed ID: 33202448
[TBL] [Abstract][Full Text] [Related]
18. Outcome after discontinuing anticoagulant therapy in women with venous thromboembolism during hormonal use.
Blanco-Molina Á; Trujillo-Santos J; Pesavento R; Rosa V; Falgá C; Tolosa C; Mazzolai L; Sampériz Á; Duce R; Monreal M;
Thromb Res; 2017 Mar; 151 Suppl 1():S6-S10. PubMed ID: 28262237
[TBL] [Abstract][Full Text] [Related]
19. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism.
Douketis JD; Gu CS; Schulman S; Ghirarduzzi A; Pengo V; Prandoni P
Ann Intern Med; 2007 Dec; 147(11):766-74. PubMed ID: 18056660
[TBL] [Abstract][Full Text] [Related]
20. Risk assessment for recurrence and optimal agents for extended treatment of venous thromboembolism.
Agnelli G; Becattini C
Hematology Am Soc Hematol Educ Program; 2013; 2013():471-7. PubMed ID: 24319221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
